Secondary Stock Offerings
By The Online Investor Staff, updated Fri., Apr. 19, 12:21 AM
Slide #5. TScan Therapeutics, Inc. — Secondary Offering
Company: |
TScan Therapeutics, Inc. (NASDAQ:TCRX) |
Date announced: |
4/16/2024 |
Shares Offered: |
2,472,581 |
Date of Pricing: |
4/17/2024 |
Price Per Share: |
$7.13 |
Secondary Offering Details: |
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has commenced an underwritten public offering of $125 million of shares of its voting common stock and, in lieu of voting common stock, to certain investors that so choose, pre-funded warrants to purchase shares of voting common stock. All shares of voting common stock and pre-funded warrants to be sold in the offering will be offered by TScan. TScan intends to grant the underwriters a 30-day option to purchase additional shares of its voting common stock in an amount equal to 15% of the securities offered in the public offering. The offering is subject to market, regulatory and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 4/17- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 2,472,581 shares of its voting common stock at a public offering price of the market price of $7.1300 per share, which was equal to the closing price of its voting common stock on the Nasdaq Global Market on April 16, 2024, and pre-funded warrants to purchase up to an aggregate of 18,577,419 shares of its voting common stock at a price to the public of $7.1299 per pre-funded warrant to purchase one share of the voting common stock, which represents the per share public offering price for the voting common stock less the $0.0001 per share exercise price for each such pre-funded warrant. In addition, TScan has granted the underwriters a 30-day option to purchase up to an additional 3,157,500 shares of its voting common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to TScan from this offering are expected to be approximately $150.1 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by TScan, assuming no exercise of the underwriters' option to purchase additional shares of voting common stock. The offering is expected to close on or about April 19, 2024, subject to customary closing conditions. |
TScan Therapeutics is a clinical-stage biopharmaceutical company focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. Co.'s proprietary platform is designed to: discover anti-cancer TCRs from patients with exceptional responses to immunotherapy; discover TCRs that recognize clinically validated targets; identify off-targets of TCRs to eliminate candidates; and manufacture TCR-T therapies using Co.'s T-Integrate technology. The central elements of Co.'s platform that differentiate it from other cell therapy companies are TargetScan, ReceptorScan, SafetyScan, ImmunoBank and T-Integrate.
Open the TCRX Page at The Online Investor »
Company Name: |
TScan Therapeutics Inc |
Website: |
www.tscan.com |
Sector: |
Biotechnology |
Number of ETFs Holding TCRX: |
4 |
Total Market Value Held by ETFs: |
$15.71M |
Total Market Capitalization: |
$311.00M |
% of Market Cap. Held by ETFs: |
5.05% |
|
Open the TCRX Page at The Online Investor (in a new window) »
|
April 19, 2024 12:21 AM Eastern
Strong Buy (4.00 out of 4)
100th percentile
|
|